BJDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Bluejay Diagnostics Inc (BJDX) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are bearish, the financial performance is weak, and there are no significant positive catalysts or trading signals to support an immediate investment. It is better to monitor the stock for further developments, particularly FDA clearance for its IL-6 test candidate or improvements in financial performance.
The MACD is below 0 and negatively contracting, indicating bearish momentum. The RSI is neutral at 29.23, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 1.883, and resistance is at 2.823. Overall, the technical indicators suggest a bearish trend.
The company has exercised all prefunded warrants from its October 2025 private placement, which may enhance financial flexibility. Additionally, the IL-6 test candidate has potential if it receives FDA clearance.
The company has not yet received FDA clearance for its IL-6 test candidate, which could delay its commercialization. The recent reverse stock split may also affect market perceptions. Financial performance remains weak with negative EPS and net income.
In Q3 2025, revenue remained at 0 with no growth. Net income improved slightly to -1,597,632 (up 7.81% YoY), but EPS dropped significantly to -4.06 (down -86.91% YoY). Gross margin remains at 0, indicating no profitability.
No data available for analyst ratings or price target changes.
